HotSpot Therapeutics

HotSpot Therapeutics

  • Founded: 2017
  • Location: Boston, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin1/Clin2
  • Therapy area: Advanced solid tumors
  • Drug types: IMM, ONC, RHU, MUS
  • Lead product: HST-1011
  • Product link:
  • Funding: $100M C Nov 2021; $65M B May 2020; $45M A Jul 2018

job board

Short description:

Small Molecules designed for Distinct Protein Domains

Drug notes:

Undisclosed RD autoimmune diseases; Undisclosed RD oncology

Long description:

HotSpot Therapeutics is pioneering a new approach to allosteric drug discovery. Many proteins have on/off switches called “natural hotspots” that are critical to a protein’s endogenous function. HotSpot is targeting these “natural hotspots” on proteins that are decisive in the control of cellular pathways and linked to various diseases. To achieve this, HotSpot is using their technology platform, Smart AllosteryTM, which is designed to systematically identify and drug natural hotspots across the proteome, including protein classes largely considered undruggable. HotSpot’s initial focus is on treating cancer and autoimmune diseases with their lead candidate, HST-1011, in development for CBL-B solid tumors.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy